Patents by Inventor Carlo Boutton
Carlo Boutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132624Abstract: The present invention relates to polypeptides that are capable of binding to a specific epitope on the neonatal Fc receptor (FcRn). In particular, the present invention relates to novel and improved polypeptides comprising immunoglobulin single variable domains (ISVDs), such as heavy-chain single variable domains, that are capable of binding to a specific epitope on FcRn. The invention further relates to constructs, compounds, molecules or chemical entities that comprise at least one of these ISVDs binding to a specific epitope on FcRn. The present invention further relates to methods for producing such polypeptides as well as to uses of such polypeptides for diverse applications, including but not limited to the extension of the half-life in vivo of therapeutic compounds and/or the prevention and/or treatment of a disease and/or disorder, such as but not limited to a proliferative disease, an inflammatory disease, an infectious disease or an autoimmune disease.Type: ApplicationFiled: July 27, 2023Publication date: April 25, 2024Inventors: Tom Van Bogaert, Judith Verhelst, Stephanie Staelens, Carlo Boutton, Wilbert De Witte, Thomas Bertrand
-
Patent number: 11932702Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: December 17, 2021Date of Patent: March 19, 2024Assignees: Ablynx N.V., SanofiInventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
-
Publication number: 20230242620Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: April 13, 2023Publication date: August 3, 2023Applicants: Ablynx N.V., SanofiInventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11708404Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: April 13, 2022Date of Patent: July 25, 2023Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20230211006Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: ApplicationFiled: June 27, 2022Publication date: July 6, 2023Applicant: Ablynx N.V.Inventors: Daniel Janssen, Peter Schotte, Francis Descamps, Carlo Boutton, Peter Casteels
-
Patent number: 11649290Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 27, 2019Date of Patent: May 16, 2023Assignee: Merck Sharp & Dohme LLCInventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
-
Patent number: 11644471Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: GrantFiled: December 23, 2013Date of Patent: May 9, 2023Assignees: Ablynx N.V., SanofiInventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11485777Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: November 1, 2022Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11485778Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: December 27, 2021Date of Patent: November 1, 2022Assignees: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220332807Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 25, 2022Publication date: October 20, 2022Applicants: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220332806Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 17, 2022Publication date: October 20, 2022Applicants: Ablynx N.V., SanofiInventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220324951Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISV” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.Type: ApplicationFiled: March 17, 2022Publication date: October 13, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11466089Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2017Date of Patent: October 11, 2022Assignee: Ablynx N.V.Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Publication number: 20220298227Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: September 22, 2022Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11426468Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: GrantFiled: December 18, 2015Date of Patent: August 30, 2022Assignee: Ablynx N.V.Inventors: Daniel Janssen, Peter Schotte, Francis Descamps, Carlo Boutton, Peter Casteels
-
Publication number: 20220251183Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: April 13, 2022Publication date: August 11, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220213215Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: December 17, 2021Publication date: July 7, 2022Applicants: Ablynx N.V., SanofiInventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
-
Publication number: 20220135657Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 29, 2021Publication date: May 5, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11319364Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: May 3, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11312764Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: November 26, 2019Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton